French Doctors Offered New Drugs Deal By Govt

6 January 1997

France's government has published a a decree defining the principleswhich will control medical spending from 1997. In cases where there is a marked overshooting of the 1.3% spending growth limit fixed for 1997, the doctors themselves will be held responsible collectively for the reversal of this position, French sources note.

The principle of one collective sanction - which earlier led to a breakdown in negotiations with the medical professions' main representative bodies (Marketletters passim) - is being maintained. However, Social Affairs Minister Jacques Barrot has softened the conditions under which the sanction will be applied. Doctors will only be required to refund 5% of the value of excess prescriptions in place of the 20% envisaged initially.

And the doctors have been invited to negotiate a basis for individual modification of the sanctions so as not to penalize the more virtuous members of the profession. In other words, all French doctors are equal before the principle of financial sanctions but some will be more equal than others.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight